| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 26.03M |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 1.03M | 988K | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | -1.03M | -988K | 26.03M |
| Gross Margin % | - | - | - | - | - | 1% |
| Gross Profit Growth % | - | - | - | - | 0.04% | 27.35% |
| Operating Expenses | 16.44M | 29.36M | 97.59M | 114.69M | 62.07M | 48.48M |
| OpEx % of Revenue | - | - | - | - | - | 1.86% |
| Selling, General & Admin | 1.41M | 7.31M | 19.23M | 20.37M | 13.53M | 19.23M |
| SG&A % of Revenue | - | - | - | - | - | 0.74% |
| Research & Development | 15.44M | 23.12M | 81.34M | 95.26M | 51.91M | 29.26M |
| R&D % of Revenue | - | - | - | - | - | 1.12% |
| Other Operating Expenses | -411.44K | -1.07M | -2.98M | -940.31K | -4.35M | 0 |
| Operating Income | -15.99M | -30.3M | -99.15M | -117.66M | -62.07M | -22.45M |
| Operating Margin % | - | - | - | - | - | -0.86% |
| Operating Income Growth % | - | -0.89% | -2.27% | -0.19% | 0.47% | 0.64% |
| EBITDA | -15.88M | -30.07M | -98.51M | -116.65M | -61.09M | -21.79M |
| EBITDA Margin % | - | - | - | - | - | -0.84% |
| EBITDA Growth % | - | -0.89% | -2.28% | -0.18% | 0.48% | 0.64% |
| D&A (Non-Cash Add-back) | 114.61K | 221.05K | 640.98K | 1.01M | 988K | 660K |
| EBIT | -24.4M | -112.48M | -202.36M | -118.04M | -59.36M | -22.45M |
| Net Interest Income | 146.96K | 103.4K | 90.76K | 1.54M | 5.2K | 4.45M |
| Interest Income | 154.65K | 109.84K | 97.67K | 1.56M | 5.2K | 4.45M |
| Interest Expense | 7.69K | 6.43K | 6.91K | 21.03K | 0 | 0 |
| Other Income/Expense | -8.41M | -89.07M | -103.21M | -403.66K | 2.69M | 7.05M |
| Pretax Income | -24.46M | -119.37M | -204.94M | -116.12M | -59.38M | -15.4M |
| Pretax Margin % | - | - | - | - | - | -0.59% |
| Income Tax | -442.49K | 934.46K | 266.47K | 297.52K | 120K | 223K |
| Effective Tax Rate % | 0.98% | 1.01% | 1% | 1% | 1% | 1.01% |
| Net Income | -24.02M | -120.3M | -205.21M | -116.42M | -59.5M | -15.63M |
| Net Margin % | - | - | - | - | - | -0.6% |
| Net Income Growth % | - | -4.01% | -0.71% | 0.43% | 0.49% | 0.74% |
| Net Income (Continuing) | -24.4M | -112.89M | -202.63M | -118.37M | -59.5M | -15.63M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.02 | -14.45 | -25.00 | -14.50 | -1.08 | -0.28 |
| EPS Growth % | - | -3.78% | -0.73% | 0.42% | 0.93% | 0.74% |
| EPS (Basic) | -3.02 | -14.45 | -25.00 | -14.50 | -1.08 | -0.28 |
| Diluted Shares Outstanding | 55.82M | 53.94M | 52.27M | 55.04M | 55.07M | 55.21M |
| Basic Shares Outstanding | 55.82M | 53.94M | 52.27M | 55.04M | 55.07M | 55.21M |
| Dividend Payout Ratio | - | - | - | - | - | - |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Total Current Assets | 52.64M | 161.89M | 275.44M | 158.46M | 122.55M | 96.96M |
| Cash & Short-Term Investments | 49.27M | 156.74M | 268.02M | 164.65M | 118.65M | 93.71M |
| Cash Only | 44.82M | 154.73M | 268.02M | 80.37M | 105.66M | 78.23M |
| Short-Term Investments | 4.44M | 2M | 0 | 74.67M | 12.65M | 15.48M |
| Accounts Receivable | 0 | 0 | 7.41M | 0 | 351K | 1.05M |
| Days Sales Outstanding | - | - | - | - | - | 14.74 |
| Inventory | 3.18M | 4.88M | -6.74K | -6.42M | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 54K | 53K |
| Total Non-Current Assets | 1.42M | 4.3M | 15.94M | 18.55M | 4.82M | 4.32M |
| Property, Plant & Equipment | 496.45K | 2.68M | 12.9M | 5.47M | 4.74M | 4.24M |
| Fixed Asset Turnover | - | - | - | - | - | 6.14x |
| Goodwill | 0 | 0 | -3.45M | 0 | 0 | 0 |
| Intangible Assets | 0 | 52.39K | 3.54M | 3.22M | 62K | 53K |
| Long-Term Investments | 0 | 0 | 0 | 9.6M | 0 | 0 |
| Other Non-Current Assets | 921.82K | 1.57M | 2.95M | 34.62K | 132K | 33K |
| Total Assets | 54.05M | 166.19M | 291.39M | 177.01M | 125.89M | 101.28M |
| Asset Turnover | - | - | - | - | - | 0.26x |
| Asset Growth % | - | 2.07% | 0.75% | -0.39% | -0.29% | -0.2% |
| Total Current Liabilities | 3.97M | 5.82M | 18.01M | 15.89M | 25.29M | 8.46M |
| Accounts Payable | 3.27M | 3.77M | 12.73M | 11.94M | 7.66M | 342K |
| Days Payables Outstanding | - | - | - | 4.23K | 2.83K | - |
| Short-Term Debt | 0 | 92.53K | 0 | 0 | 0 | 154K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 1000K | 164K |
| Other Current Liabilities | 509.99K | -98.31K | 5.15M | 2.69M | 2.05M | 3.19M |
| Current Ratio | 13.24x | 27.81x | 15.30x | 9.97x | 4.85x | 11.46x |
| Quick Ratio | 12.44x | 26.97x | 15.30x | 10.37x | 4.85x | 11.46x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 93.35M | 317.38M | 810.73K | 911.83K | 585K | 656K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 67.17K | 47.3K | 26K | 245K | 180K | 24K |
| Deferred Tax Liabilities | 0 | 0 | -782.42K | -656.85K | 0 | 0 |
| Other Non-Current Liabilities | 91.9M | 317.33M | 784K | 0 | 0 | 632K |
| Total Liabilities | 97.33M | 323.2M | 18.82M | 16.81M | 24.85M | 9.12M |
| Total Debt | 127.96K | 139.86K | 124.52K | 437.88K | 465K | 178K |
| Net Debt | -44.7M | -154.59M | -267.9M | -79.93M | -105.54M | -78.05M |
| Debt / Equity | - | - | 0.00x | - | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - |
| Interest Coverage | -2080.02x | -4708.64x | -14350.83x | -5594.41x | - | - |
| Total Equity | -43.27M | -157.01M | 272.57M | -463.76M | 101.04M | 92.17M |
| Equity Growth % | - | -2.63% | 2.74% | -2.7% | 1.22% | -0.09% |
| Book Value per Share | -0.78 | -2.91 | 5.21 | -8.43 | 1.83 | 1.67 |
| Total Shareholders' Equity | -43.27M | -157.01M | 272.57M | -463.76M | 101.04M | 92.17M |
| Common Stock | 3.05K | 3.68K | 10.36K | 9.64K | 10K | 10K |
| Retained Earnings | -42.38M | -164.12M | -373.43M | -463.76M | -329.73M | -345.36M |
| Treasury Stock | -144 | -460 | -180K | -180K | -180K | -180K |
| Accumulated OCI | -7.07M | -259.35K | -6.48M | 10.39M | 11.85M | -1.67M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Cash from Operations | -13.09M | -25.61M | -85.57M | -99.27M | -47.93M | -23.61M |
| Operating CF Margin % | - | - | - | - | - | -0.91% |
| Operating CF Growth % | - | -0.96% | -2.34% | -0.16% | 0.52% | 0.51% |
| Net Income | -24.46M | -119.37M | -204.94M | -116.12M | -59.38M | -15.63M |
| Depreciation & Amortization | 114.61K | 221.05K | 640.98K | 1.01M | 988K | 660K |
| Stock-Based Compensation | 562.17K | 590.64K | 1.41M | 1.01M | 3.26M | 6.73M |
| Deferred Taxes | 8.3M | 89.68M | 106.37M | 3.37M | 0 | 0 |
| Other Non-Cash Items | 7.69K | 443.18K | 6.91K | -1.35M | -2.28M | 118K |
| Working Capital Changes | 2.38M | -436.29K | 3.27M | 7.16M | 9.48M | -15.49M |
| Change in Receivables | -439 | -1.43K | -2.53K | 3.37K | 1.04M | -789K |
| Change in Inventory | 439 | 1.43K | 2.53K | -3.37K | 0 | 0 |
| Change in Payables | 2.81M | 283.4K | 8.89M | 375.66K | -4.28M | -1.87M |
| Cash from Investing | -484.7K | 449.15K | -5.34M | -83.44M | 75.16M | -3.45M |
| Capital Expenditures | -155.52K | -2.34M | -7.46M | -4.28M | -294K | -750K |
| CapEx % of Revenue | - | - | - | - | - | 0.03% |
| Acquisitions | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - |
| Other Investing | -329 | -53.46K | -47.74K | -79.16K | -84K | 123K |
| Cash from Financing | -57.45K | 140.74M | 206.66M | -91.28K | -246K | 227K |
| Debt Issued (Net) | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - |
| Other Financing | 7K | 140.83M | -19.12M | 119K | 0 | 0 |
| Net Change in Cash | - | - | - | - | - | - |
| Free Cash Flow | -13.25M | -27.95M | -93.03M | -103.55M | -48.22M | -24.36M |
| FCF Margin % | - | - | - | - | - | -0.94% |
| FCF Growth % | - | -1.11% | -2.33% | -0.11% | 0.53% | 0.49% |
| FCF per Share | -0.24 | -0.52 | -1.78 | -1.88 | -0.88 | -0.44 |
| FCF Conversion (FCF/Net Income) | 0.55x | 0.21x | 0.42x | 0.85x | 0.81x | 1.51x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 462K | 120K | 111K |
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -355.15% | - | -58.89% | -16.18% |
| Return on Invested Capital (ROIC) | - | - | -1592.18% | - | - | -338.23% |
| Gross Margin | - | - | - | - | - | 100% |
| Net Margin | - | - | - | - | - | -60.03% |
| Debt / Equity | - | - | 0.00x | - | 0.00x | 0.00x |
| Interest Coverage | -2080.02x | -4708.64x | -14350.83x | -5594.41x | - | - |
| FCF Conversion | 0.55x | 0.21x | 0.42x | 0.85x | 0.81x | 1.51x |
| 2024 | |
|---|---|
| License | 24.4M |
| License Growth | - |
Connect Biopharma Holdings Limited (CNTB) reported $26.1M in revenue for fiscal year 2024.
Connect Biopharma Holdings Limited (CNTB) grew revenue by 0.0% over the past year. Growth has been modest.
Connect Biopharma Holdings Limited (CNTB) reported a net loss of $57.4M for fiscal year 2024.
Connect Biopharma Holdings Limited (CNTB) has a return on equity (ROE) of -16.2%. Negative ROE indicates the company is unprofitable.
Connect Biopharma Holdings Limited (CNTB) had negative free cash flow of $54.0M in fiscal year 2024, likely due to heavy capital investments.